237 completed, 180 active not recruiting, 143 recruiting, 77 unknown. 520 Phase 2, 234 Phase 1, 101 Phase 3, 11 Early Phase 1, 9 Not applicable.
Follow durvalumab: new trials by email Literature Review of durvalumab trials Research Report on durvalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab - Gastroesophageal Adenocarcinoma | Phase 2 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 184 | 2027-01-01 | 2026-07-10 |
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-09-17 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. FLOT Chemotherapy, Durvalumab - Gastric, Esophagogastric Junction | Phase 3 | Not yet recruiting | AstraZeneca | 140 | 2026-11-30 | 2026-10-16 |
| Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer CAPP-Seq technique, Durvalumab - Non-small Cell Lung Cancer Stage III Unresectable | Phase 2 | Not yet recruiting | Intergroupe Francophone de Cancerologie Thoracique | 177 | 2026-11-01 | 2026-08-12 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-10-27 | 2026-10-22 |
| A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive Durvalumab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Cancer (MIBC) | Phase 4 | Not yet recruiting | AstraZeneca | 50 | 2026-10-20 | 2026-10-15 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| Histotripsy in Biliary Tract Cancer Gemcitabine, Cisplatin, Durvalumab - Biliary Track Cancer | Not applicable | Recruiting | NYU Langone Health | 24 | 2026-10-05 | 2026-10-20 |
| Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma Histotripsy, Durvalumab, Biopsy - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | University of Wisconsin, Madison | 12 | 2026-10-01 | 2026-10-13 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-10-01 | 2026-10-05 |
| A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC IMFINZI - Carcinoma, Non-Small-Cell Lung | Not yet recruiting | AstraZeneca | 78 | 2026-09-30 | 2026-08-12 | |
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2026-09-15 | 2026-08-06 |
Showing 20 of 794. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (161) · Lung Neoplasms (73) · Carcinoma, Hepatocellular (64) · Small Cell Lung Carcinoma (54) · Breast Neoplasms (47) · Squamous Cell Carcinoma of Head and Neck (36) · Biliary Tract Neoplasms (31) · Urinary Bladder Neoplasms (31) · Cholangiocarcinoma (30) · Colorectal Neoplasms (30) · Neoplasms (29) · Neoplasm Metastasis (28) · Pancreatic Neoplasms (26) · Triple Negative Breast Neoplasms (25) · Ovarian Neoplasms (24)
AstraZeneca (120) · MedImmune LLC (28) · National Cancer Institute (NCI) (26) · M.D. Anderson Cancer Center (25) · Memorial Sloan Kettering Cancer Center (17) · Canadian Cancer Trials Group (15) · University Health Network, Toronto (10) · Celgene (9) · Ludwig Institute for Cancer Research (9) · Seoul National University Hospital (9) · UNICANCER (8) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (7) · Washington University School of Medicine (7) · Yonsei University (7) · Eli Lilly and Company (6)
United States (435) · France (151) · South Korea (139) · Spain (139) · Canada (128) · Italy (114) · Germany (106) · China (99) · Taiwan (90) · United Kingdom (86) · Japan (81) · Australia (76) · Belgium (71) · Poland (70) · Netherlands (63)
Lillian Siu, MD (4) · Tim F Greten, M.D. (4) · Do-Youn Oh, MD, PhD (3) · Haiyi Jiang, M.D. (3) · Jared Weiss, MD (3) · Narek Shaverdian, MD (3) · Nina Bhardwaj, MD, PhD (3) · Patrick Forde, MD (3) · Salah-Eddin Al-Batran, Prof. Dr. (3) · Vassiliki Papadimitrakopoulou (3)
PMID 32816849, PMID 26410619, PMID 28817753, PMID 28885881, PMID 32203306, PMID 32379297, PMID 32450725, PMID 33319498, PMID 34499875, PMID 34515338, PMID 34904813, PMID 35623069, PMID 37185961, PMID 39615497, PMID 41861260, PMID 10673991, PMID 14639532, PMID 16773629, PMID 17997439, PMID 19097774, PMID 20697067, PMID 21555688, PMID 21796368, PMID 22065672, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23770567, PMID 24209604, PMID 24472710, PMID 24476821, PMID 25428503, PMID 26487582, PMID 26541610, PMID 26858122, PMID 27140411, PMID 27262113, PMID 27269937, PMID 27324051, PMID 27345655, PMID 27406346, PMID 27406347, PMID 27622077, PMID 27726966, PMID 27764686, PMID 28078238, PMID 28259287, PMID 28271869, PMID 28337197, PMID 28481359
2018 (36), 2023 (28), 2019 (20), 2015 (19), 2017 (19), 2016 (12), 2025 (8), U10CA180868 (7), 2014 (6), U10CA180888 (6), U10CA180820 (5), P30CA060553 (4), P30CA015704 (3), P30CA138292 (3), P30CA012197 (2)